Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML) is a federal award for 262-Network Contract Office 22 (36C262) held by Novartis Pharmaceuticals Corp. Estimated value $5M ($1M obligated). Current period of performance ends Jan 1, 2027. Last award drew 1 bidder. Place of performance: PHOENIX AZ.
PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML)
Recompete timing
PublicCurrent PoP ends Jan 1, 2027 (92 days remaining). Agencies typically plan 12–18 months ahead — at 3.0 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on 36C26226F0048? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordNovartis Pharmaceuticals Corp — $23.5M obligated across 59 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C26226F0048?
36C26226F0048 (Pluvicto (lutetium LU 177 vipivotide TETRA) is a 262-Network Contract Office 22 (36C262) award with a potential value of $5M, currently held by Novartis Pharmaceuticals Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C262-26-F-0048?
36C262-26-F-0048 is the dashed form of PIID 36C26226F0048 (Pluvicto (lutetium LU 177 vipivotide TETRA), held by Novartis Pharmaceuticals Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C26226F0048?
262-Network Contract Office 22 (36C262) awarded 36C26226F0048 to Novartis Pharmaceuticals Corp (potential $5M).
Who is the incumbent on 36C26226F0048?
Novartis Pharmaceuticals Corp is the incumbent with $23.5M across 59 related awards in SCOUT’s public footprint. The current period of performance ends Jan 1, 2027.
When does Novartis Pharmaceuticals Corp’s 36C26226F0048 come up for recompete?
SCOUT tracks a period-of-performance end of Jan 1, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 36C26226F0048? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.